BEOVU (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
BEOVU
Date registered
Evaluation commenced
Decision date
Approval time
189 working days (255)
Active ingredients
brolucizumab
Registration type
NCE/NBE
Indication
BEOVU (solution for injection) is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).